About Response Genetics, Inc.Response Genetics Inc. (“RGI”) is a CLIA-certified clinical laboratory focused on the development and sale of molecular diagnostic tests for cancer. RGI’s principal customers include oncologist, pathologists and hospitals. In addition to diagnostic testing services, the Company generates revenue from the sales of its analytical testing services of clinical trial specimens to the pharmaceutical industry. RGI was founded in 1999 and its principal headquarters are located in Los Angeles, California. For additional information, please visit www.responsegenetics.com. Forward-Looking Statement Notice Except for the historical information contained herein, this press release and the statements of representatives of RGI related thereto contain or may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company’s plans, objectives, projections, expectations and intentions, such as the ability of the Company to continue to execute on its business strategy and operations, the ability to expand our test panels, the ability , and other statements identified by words such as “projects,” “may,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans” or similar expressions. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission. Actual results, including, without limitation, actual sales results, if any, or the application of funds, may differ from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company’s control). The Company undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law.
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and commercialization of molecular diagnostic tests for cancer, announced today the addition of Stephanie H. Astrow, Ph.D., as the Company’s Vice President for Research and Development. In her role, Dr. Astrow will be responsible for leading the company’s research and development programs, as well as identifying and incorporating new technologies into the services that the Company provides to the medical community. “With her strong background in the oncology molecular diagnostics industry we believe Stephanie is the perfect fit to lead our R&D efforts,” said Thomas Bologna, Chairman and Chief Executive Officer of Response Genetics. “Stephanie’s track record of identifying and developing biomarker assays and driving scientific innovation to expand business will be a tremendous asset to us and we are looking forward to her contributions.” Dr. Astrow brings extensive experience in molecular diagnostics research and development as well as operational experience to her role at Response Genetics. Most recently, Dr. Astrow was Scientific Director for Oncology at Quest Diagnostics, the largest global provider of diagnostic testing. At Quest, she played a key role in expanding business by introducing new assays and services, as well as coordinating development strategy for companion diagnostics with key pharmaceutical companies. Prior to her work at Quest, Dr. Astrow served as Vice President and Director of Oncology at Pathway Diagnostics, and Vice President, Scientific Director of Impath, Inc. Dr. Astrow received a Bachelor of Arts in Biology and Medicine at Brown University, and her Ph.D. in Molecular and Cell Biology from the University of California, Berkeley. She also holds a Masters of Business Administration from Pepperdine University. Dr. Astrow, commenting on her appointment said, “I couldn’t be more excited to be joining Response Genetics, a company that matches my background and interests very well. I look forward to putting my skills and experience to work in helping people with cancer, and being part of a company that is both patient-centric and well suited to prosper in the exciting field of personalized diagnostics.”